HKD18.54
0.76% today
Hong Kong, Apr 03, 10:08 am CET
ISIN
CNE100000FN7
Symbol
1099
Index
Sector
Industry

Sinopharm Group Target price 2025 - Analyst rating & recommendation

Sinopharm Group Classifications & Recommendation:

Buy
71%
Hold
24%
Sell
6%

Sinopharm Group Price Target

Target Price HKD22.28
Price HKD18.54
Potential
Number of Estimates 15
15 Analysts have issued a price target Sinopharm Group 2026 . The average Sinopharm Group target price is HKD22.28. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 12 Analysts recommend Sinopharm Group to buy, 4 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sinopharm Group stock has an average upside potential 2026 of . Most analysts recommend the Sinopharm Group stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion HKD 633.74 652.07
3.86% 2.89%
EBITDA Margin 3.77% 3.38%
13.99% 10.35%

16 Analysts have issued a sales forecast Sinopharm Group 2025 . The average Sinopharm Group sales estimate is

HKD652b
Unlock
. This is
2.89% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD696b 9.90%
Unlock
, the lowest is
HKD619b 2.33%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 HKD634b 3.86%
2025
HKD652b 2.89%
Unlock
2026
HKD683b 4.78%
Unlock
2027
HKD712b 4.25%
Unlock

14 Analysts have issued an Sinopharm Group EBITDA forecast 2025. The average Sinopharm Group EBITDA estimate is

HKD22.0b
Unlock
. This is
7.78% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD27.9b 16.71%
Unlock
, the lowest is
HKD14.2b 40.38%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 HKD23.9b 17.31%
2025
HKD22.0b 7.80%
Unlock
2026
HKD23.2b 5.10%
Unlock
2027
HKD24.7b 6.46%
Unlock

EBITDA Margin

2024 3.77% 13.99%
2025
3.38% 10.35%
Unlock
2026
3.39% 0.30%
Unlock
2027
3.46% 2.06%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share HKD 2.45 2.65
23.68% 8.16%
P/E 6.93
EV/Sales 0.24

7 Analysts have issued a Sinopharm Group forecast for earnings per share. The average Sinopharm Group EPS is

HKD2.65
Unlock
. This is
8.16% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
HKD2.91 18.78%
Unlock
, the lowest is
HKD2.48 1.22%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 HKD2.45 23.68%
2025
HKD2.65 8.16%
Unlock
2026
HKD2.86 7.92%
Unlock
2027
HKD3.16 10.49%
Unlock

P/E ratio

Current 7.51 19.97%
2025
6.93 7.72%
Unlock
2026
6.44 7.07%
Unlock
2027
5.82 9.63%
Unlock

Based on analysts' sales estimates for 2025, the Sinopharm Group stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.25 8.70%
2025
0.24 2.24%
Unlock
2026
0.23 4.58%
Unlock
2027
0.22 4.07%
Unlock

P/S ratio

Current 0.09 4.43%
2025
0.09 2.76%
Unlock
2026
0.08 4.65%
Unlock
2027
0.08 4.05%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today